GeneDx Holdings (WGS)

Healthcare · Diagnostics & Research
$67.33 -0.59% on the day Market cap $2.4B 52-week range $32.21 to $170.87 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
34% a year for 10 years

At a market value of $2.4B, GeneDx Holdings's free cash flow of $14M (fiscal 2025) would need to grow about 34% a year for the stock to be worth today's price.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from GeneDx Holdings's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price33.8% a year
Free cash flow, last – years—
Revenue, same period13.9% a year
Price to free cash flow170.4x

Fundamental grade

F

Five factors scored 1 to 9 from WGS's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation2
Profitability2
Growth2
Financial health7
Cash efficiency4

Results from SEC filings

Fiscal years, from GeneDx Holdings's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue$212M$235M$203M$305M$428M
Net income-$245M-$549M-$176M-$52M-$21M
Free cash flow-$211M-$333M-$186M-$34M$14M
EPS (diluted)-$2.27-$53.63-$7.23-$1.94-$0.73
Operating margin-210.3%-284.5%-89.2%-7.6%-3.1%

Where the revenue comes from

Revenue by segments, fiscal 2025. Every breakdown, year by year.

GeneDx$423M99%
Other$4M1%

Superinvestors who own WGS

From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Cliff Asness
AQR Capital Management
Added $2M0.00%Q2 2026

Insider buying

Open-market purchases by GeneDx Holdings's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Mar 5, 2026 Keith A Meister
140,026$81.19$11M
Mar 3, 2026 Keith A Meister
29,495$70.89$2M

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when WGS trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does GeneDx Holdings's stock price imply?

At a market value of $2.4B, GeneDx Holdings would need its free cash flow to grow about 34% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price.

Are GeneDx Holdings insiders buying the stock?

2 open-market insider purchases of WGS in the last 12 months, from SEC Form 4 filings.

Which superinvestors own GeneDx Holdings?

1 of the superinvestors Investingly tracks hold WGS in their latest 13F, including Cliff Asness.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.